The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions-Reference-Cited by-同舟云学术

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions

Published:2014-07-29 Issue:14 Volume:42 Page:9108-9120
ISSN:0305-1048
Container-title:Nucleic Acids Research
language:en
Short-container-title:Nucleic Acids Res

Author:

Orta Manuel Luis,Höglund Andreas,Calderón-Montaño José Manuel,Domínguez Inmaculada,Burgos-Morón Estefanía,Visnes Torkild,Pastor Nuria,Ström Cecilia,López-lázaro Miguel,Helleday Thomas

Publisher

Oxford University Press (OUP)

Subject

Genetics

Link

http://academic.oup.com/nar/article-pdf/42/14/9108/14123835/gku638.pdf

Reference45 articles.

1. Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia

2. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

3. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

4. 5-azacytidine, a new, highly effective cancerostatic;Šorm;Experientia,1964

5. Cellular differentiation, cytidine analogs and DNA methylation

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia;Frontiers in Pharmacology;2024-08-08

2. Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient;Leukemia & Lymphoma;2024-07-02

3. Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent Tumors;2024-06-28

4. The type of DNA damage response after decitabine treatment depends on the level of DNMT activity;Life Science Alliance;2024-06-21

5. Decitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS;The EMBO Journal;2024-05-17